The recent close of $86.09 is approximately 267% above the fair value buy target for the stock and approximately 79% above the fair value close target for the stock. The recent close is also 14% below analysts' twelve-month $100.00 median price target for the stock.
The recent close represents a 34% increase in price since the last baseline equity review was conducted in February of 2012.
The stock currently has a trailing twelve-month PE Ratio of 13, and a PEG Ratio of 0.7 basis estimated forward earnings growth of 17.50%.
In the past 52 weeks, share prices have moved between a high of $91.11 and a low of $65.15, placing equilibrium at $83.07.
Basis the recent close, the stock is trading 6% below the 52 week high, 24% above the 52 week low, 4% above equilibrium, and has an average daily trading volume of approximately 980,000 shares.
Ashland, Inc. a specialty chemical company, provides specialty chemicals, technologies, and insights for customer needs worldwide.
The company's competitors include Arkema, Brenntag AG, and Momentive Specialty Chemicals, Inc..
Financial information that may be contained herein, is based on the company's most recent annual SEC filing for year ending September 30, 2012. All prices are per share unless otherwise noted.
Wax Ink currently has no investment position in the company mentioned in this alert.
Wax Ink is a baseline equity research company comprised of individual investors, NOT licensed or registered with ANY government agency.
For use by Accredited Investors as defined under Title 17, CFR §230.500, Regulation D
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.